Core Viewpoint - Green Leaf Pharmaceutical experienced a 4.02% decline in stock price, closing at 3.82 CNY per share with a trading volume of 302 million CNY on August 20 [1] Company Overview - Green Leaf Pharmaceutical Group Limited focuses on the development, production, promotion, and sales of innovative drugs in four major therapeutic areas: oncology, central nervous system, cardiovascular system, and digestive and metabolic diseases [1] - The company has a product portfolio of over 30 products, distributed across more than 80 countries and regions globally [1] Operational Highlights - In 2021, the company's product sales reached all 30 provinces, autonomous regions, and municipalities in China, supported by approximately 1,000 sales and marketing personnel and a network of about 1,780 distributors [1] - The products are sold to over 19,330 hospitals, with international market coverage extending to 80 countries or regions [1] Financial Performance - As of the 2024 annual report, Green Leaf Pharmaceutical reported total revenue of 6.061 billion CNY and a net profit of 472 million CNY [1]
绿叶制药(02186)下跌4.02%，报3.82元/股